文献速递MDS 与骨髓增殖性肿瘤

CD34阳性血细胞上CXCR4表达降低可预测原发性骨髓纤维化患者的结局

Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis.
PubMed 文献 · Leukemia · 2020-06-14

该研究在大量骨髓增殖性肿瘤患者中分析CD34阳性血细胞CXCR4表面表达比例(CD34/CXCR4-se)的意义。原发性骨髓纤维化(PMF)患者CD34/CXCR4-se均值低于原发性血小板增多症(ET)或真性红细胞增多症(PV)患者,39%截断值诊断纤维化前PMF vs ET的阳性预测值为97%。基于年龄>65岁、血红蛋白<100 g/L、CD34阳性血细胞>50×10⁶/L和CD34/CXCR4-se<39%构建的预后模型较国际预后评分系统更准确识别三个风险组。

要点

  • PMF患者CD34/CXCR4-se均值低于ET或PV患者。
  • 39%截断值诊断纤维化前PMF vs ET的阳性预测值为97%。
  • 预后模型含年龄>65岁、血红蛋白<100 g/L、CD34阳性血细胞>50×10⁶/L和CD34/CXCR4-se<39%。

核心结论

  • CD34/CXCR4-se是PMF疾病活动性的高度敏感标志物,也是新的潜在诊断和预后生物标志物。

研究设计与样本

  • 在大量骨髓增殖性肿瘤患者队列中,采用流式细胞术评估CD34阳性血细胞中CXCR4表面表达阳性的百分比(CD34/CXCR4-se)。

主要发现

  • PMF患者CD34/CXCR4-se均值低于ET或PV患者。
  • 39%截断值诊断纤维化前PMF vs ET的阳性预测值为97%。
  • 在PMF中,男性、年龄较大和MPL突变是CD34/CXCR4-se降低的独立相关因素,并与进展至重度贫血、巨脾、血小板减少、白细胞减少、CD34阳性血细胞升高、原始细胞转化和死亡的时间间隔较短相关。
  • 包含年龄>65岁、血红蛋白<100 g/L、CD34阳性血细胞>50×10⁶/L和诊断时CD34/CXCR4-se<39%的预后模型识别出三个风险组,较国际预后评分系统更准确。

关键数值与推荐

  • CD34/CXCR4-se截断值39%用于诊断纤维化前PMF vs ET,阳性预测值97%。
  • 预后模型纳入年龄>65岁、血红蛋白<100 g/L、CD34阳性血细胞>50×10⁶/L和CD34/CXCR4-se<39%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The expression of the CXCR4 chemokine receptor on CD34-positive blood cells is reduced in persons with primary myelofibrosis (PMF). We analyzed the relevance of cytofluorimetric assessment of the percentage of CD34-positive blood cells that had a positive CXCR4 surface expression (CD34/CXCR4-se) in a large cohort of subjects with myeloproliferative neoplasms. Mean CD34/CXCR4-se was lower in subjects with PMF compared with those with essential thrombocythemia (ET) or polycythemia vera (PV). A cutoff value of 39% was associated with a diagnosis of pre-fibrotic PMF vs. ET with a positive predictive value of 97%. In PMF male sex, older age, and MPL mutation were independent correlates of reduced CD34/CXCR4-se and associated with a briefer interval to development of severe anemia, large splenomegaly, thrombocytopenia, leukopenia, elevated CD34-positive blood cells, blast transformation and death. We constructed a prognostic model including age >65 years, hemoglobin < 100 g/L, CD34-positive blood cells > 50 × 106/L, and CD34/CXCR4-se <39% at diagnosis. The model identified three risk cohorts with greater accuracy compared with the International Prognostic Scoring System. In conclusion, CD34/CXCR4-se is a highly sensitive marker of disease activity and a new potential diagnostic and prognostic biomarker in PMF.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Barosi G, Rosti V, Catarsi P, et al. Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia. 2020. PMID: 32536689. doi:10.1038/s41375-020-0926-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。